A Phase 3 interventional study of Vortioxetine in Depressive Disorder, Major, sponsored by H. Lundbeck A/S. Terminated at 78 sites in 20 countries. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-12-28.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 7th largest by enrollment, is one of 9 that started in 2016, is one of 31 in phase 3, and was the 37th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 7 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 662 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2016, is one of 21 in phase 3, and was the 28th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine tablets for 26 weeks. Single dose of vortioxetine oral drops (only a subset of participants).
Drug: Vortioxetine
Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
Also known as: Brintellix (R), Lu AA21004
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that started or increased in intensity on or after the date of first dose of study drug in this study 12712A. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.
Time frame: Baseline up to Week 30
Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 26
CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was calculated using a restricted maximum likelihood-based mixed model for repeated measurements (MMRM) approach.
Time frame: Baseline, Week 26
Time to First Relapse
Relapse was defined as a total score ≥40 on the CDRS-R. CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression).
Time frame: Baseline up to Week 26
Time to First Loss of Remission
Remission was defined as a total score ≤28 on the CDRS-R. CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression).
Time frame: Baseline up to Week 26
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 26
The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants). LS mean was calculated using a restricted maximum likelihood-based MMRM approach.
Time frame: Baseline, Week 26
Clinical Global Impression - Global Improvement (CGI-I) Score
The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). LS mean was calculated using a restricted maximum likelihood-based MMRM approach.
Time frame: Week 26
Children (7-11 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Preschool (BRIEF-P) Using the Global Executive Composite (GEC) Score at Week 26
BRIEF form is an 86-item measure with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. For BRIEF-P form, only the first 72 items (Inhibit \[10\], Shift \[8\], Emotional Control \[10\], Initiate \[8\], Working Memory \[10\], Plan/Organize \[12\], Organization of Materials \[6\], Monitor \[8\]) were included in clinical scales. Clinical scales combined to form 2 indexes, Behavioural Regulation Index (BRI) and Metacognition Index (MI), and 1 composite summary score, the GEC, that incorporates all 8 clinical scales. GEC score was calculated as the sum of index scores ranging from 72-216; higher scores indicating greater impairment in executive functions. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-P. Conversion was based on gender and age group. T-scores ranged between 30 to 101, with a lower score indicating better functioning.
Time frame: Baseline, Week 26
Adolescents (12-18 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Self-report (BRIEF-SR) Using the GEC Score at Week 26
BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. For BRIEF-SR form, only 80 items (Inhibit \[13\], Shift \[10\], Emotional Control \[10\], Initiate \[5\], Working Memory \[12\], Plan/Organize \[13\], Organization of Materials \[7\], Monitor \[10\]) were included in clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI, and 1 composite summary score, the GEC, that incorporates all 8 clinical scales. GEC score was calculated as the sum of index scores and ranges from 80-240 with higher scores indicating greater impairment in functions. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-SR. The conversion was based on gender and the age group. T-scores ranged between 29 to 104, with a lower score indicating better functioning.
Time frame: Baseline, Week 26
Children (7-11 Years): Change From Baseline in BRIEF-P Using the MI Score at Week 26
BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI. For BRIEF-P, MI is comprised of Initiate (8), Working Memory (10), Plan/Organize (12), Organization of Materials (6), and Monitor (8) scales. The MI scores are calculated as the sum of the total 44 items ranging from 44 to 132 with lower scores reflecting better functioning. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-P. The conversion was based on gender and the age group. T-scores ranged between 30 to 98, with a lower score indicating better functioning.
Time frame: Baseline, Week 26
Adolescents (12-18 Years): Change From Baseline in BRIEF-SR Using the MI Score at Week 26
BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI. For BRIEF-SR, MI is comprised of Working Memory (12), Plan/Organize (13), Organization of Materials (7), and Task Completion (10) scales. The MI scores are calculated as the sum of the total 42 items ranging from 42 to 126 with lower scores reflecting better functioning. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-SR. The conversion was based on gender and the age group. T-scores ranged between 31 to 100, with a lower score indicating better functioning.
Time frame: Baseline, Week 26
Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Week 26
The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.
Time frame: Baseline, Week 26
Change From Baseline in Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scale (PedsQL VAS) Total Score at Week 26
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using VAS. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items ranging from 0 to 10, where a lower value represents a better outcome.
Time frame: Baseline, Week 26
Number of Participants With Response to the Palatability Questionnaire
The palatability of vortioxetine oral drops was assessed after intake of a single dose (5 to 20 mg) corresponding to the participant's current vortioxetine dose (replacing the vortioxetine tablet on that day). The palatability assessment included 4 questions on the overall appreciation of a medicinal product in relation to its taste (What do you think of the taste), mouthfeel (How does medicine feel in your mouth), aftertaste (What do you think of the after taste), and smell (What do you think of the smell). The items were rated on a 5-point hedonic scale; really bad, bad, neither good or bad, good, or very good. The oral drops were considered acceptable if the mean hedonic scores were ≤3 for each aspect of palatability (taste, aftertaste, smell, and mouthfeel).
Time frame: assessed at Baseline up to Week 26, Week 26 reported
Number of Participants With Response to the Acceptability Questionnaire
The acceptability of vortioxetine oral drops was assessed after intake of a single dose (5 to 20 mg) corresponding to the participant's current vortioxetine dose (replacing the vortioxetine tablet on that day). The acceptability assessment was based on 3 items; acceptability of the taste, whether the drops were perceived as easy to take, willingness to take the drops every day (provided it was the only available formulation). For each item the response options were no, not sure, and yes. The oral drops were considered acceptable if \<60% of participants responded "no" to each of the 3 questions regarding acceptability.
Time frame: assessed at Baseline up to Week 26, Week 26 reported
| Milestone | Vortioxetine |
|---|---|
| Started | 662 |
| Received at least 1 dose of study drug | 662 |
| Completed | 526 |
| Not completed | 136 |
| Withdrew: Adverse event | 34 |
| Withdrew: Lack of efficacy | 10 |
| Withdrew: Non-compliance with study drug | 15 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Withdrawal by subject | 20 |
| Withdrew: Lost to follow-up | 13 |
| Withdrew: Rolled over to 13546a | 2 |
| Withdrew: Other than specified | 39 |
An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that started or increased in intensity on or after the date of first dose of study drug in this study 12712A. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.
| Participants | Vortioxetine |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 404 |
CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was calculated using a restricted maximum likelihood-based mixed model for repeated measurements (MMRM) approach.
| units on a scale | Vortioxetine |
|---|---|
| Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 26 | -16.05 ± 0.63 |
Relapse was defined as a total score ≥40 on the CDRS-R. CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression).
No measurements were reported for this outcome.
Remission was defined as a total score ≤28 on the CDRS-R. CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression).
No measurements were reported for this outcome.
The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants). LS mean was calculated using a restricted maximum likelihood-based MMRM approach.
| units on a scale | Vortioxetine |
|---|---|
| Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 26 | -1.48 ± 0.06 |
The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). LS mean was calculated using a restricted maximum likelihood-based MMRM approach.
| units on a scale | Vortioxetine |
|---|---|
| Clinical Global Impression - Global Improvement (CGI-I) Score | 1.72 ± 0.04 |
BRIEF form is an 86-item measure with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. For BRIEF-P form, only the first 72 items (Inhibit \[10\], Shift \[8\], Emotional Control \[10\], Initiate \[8\], Working Memory \[10\], Plan/Organize \[12\], Organization of Materials \[6\], Monitor \[8\]) were included in clinical scales. Clinical scales combined to form 2 indexes, Behavioural Regulation Index (BRI) and Metacognition Index (MI), and 1 composite summary score, the GEC, that incorporates all 8 clinical scales. GEC score was calculated as the sum of index scores ranging from 72-216; higher scores indicating greater impairment in executive functions. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-P. Conversion was based on gender and age group. T-scores ranged between 30 to 101, with a lower score indicating better functioning.
| T score | Vortioxetine |
|---|---|
| Children (7-11 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Preschool (BRIEF-P) Using the Global Executive Composite (GEC) Score at Week 26 | -7.41 ± 11.70 |
BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. For BRIEF-SR form, only 80 items (Inhibit \[13\], Shift \[10\], Emotional Control \[10\], Initiate \[5\], Working Memory \[12\], Plan/Organize \[13\], Organization of Materials \[7\], Monitor \[10\]) were included in clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI, and 1 composite summary score, the GEC, that incorporates all 8 clinical scales. GEC score was calculated as the sum of index scores and ranges from 80-240 with higher scores indicating greater impairment in functions. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-SR. The conversion was based on gender and the age group. T-scores ranged between 29 to 104, with a lower score indicating better functioning.
| T score | Vortioxetine |
|---|---|
| Adolescents (12-18 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Self-report (BRIEF-SR) Using the GEC Score at Week 26 | -7.50 ± 13.82 |
BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI. For BRIEF-P, MI is comprised of Initiate (8), Working Memory (10), Plan/Organize (12), Organization of Materials (6), and Monitor (8) scales. The MI scores are calculated as the sum of the total 44 items ranging from 44 to 132 with lower scores reflecting better functioning. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-P. The conversion was based on gender and the age group. T-scores ranged between 30 to 98, with a lower score indicating better functioning.
| T score | Vortioxetine |
|---|---|
| Children (7-11 Years): Change From Baseline in BRIEF-P Using the MI Score at Week 26 | -7.36 ± 11.98 |
BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI. For BRIEF-SR, MI is comprised of Working Memory (12), Plan/Organize (13), Organization of Materials (7), and Task Completion (10) scales. The MI scores are calculated as the sum of the total 42 items ranging from 42 to 126 with lower scores reflecting better functioning. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-SR. The conversion was based on gender and the age group. T-scores ranged between 31 to 100, with a lower score indicating better functioning.
| T score | Vortioxetine |
|---|---|
| Adolescents (12-18 Years): Change From Baseline in BRIEF-SR Using the MI Score at Week 26 | -7.18 ± 13.71 |
The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.
| units on a scale | Vortioxetine |
|---|---|
| Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Week 26 | 14.78 ± 14.29 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using VAS. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items ranging from 0 to 10, where a lower value represents a better outcome.
| units on a scale | Vortioxetine |
|---|---|
| Change From Baseline in Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scale (PedsQL VAS) Total Score at Week 26 | -1.50 ± 1.87 |
The palatability of vortioxetine oral drops was assessed after intake of a single dose (5 to 20 mg) corresponding to the participant's current vortioxetine dose (replacing the vortioxetine tablet on that day). The palatability assessment included 4 questions on the overall appreciation of a medicinal product in relation to its taste (What do you think of the taste), mouthfeel (How does medicine feel in your mouth), aftertaste (What do you think of the after taste), and smell (What do you think of the smell). The items were rated on a 5-point hedonic scale; really bad, bad, neither good or bad, good, or very good. The oral drops were considered acceptable if the mean hedonic scores were ≤3 for each aspect of palatability (taste, aftertaste, smell, and mouthfeel).
| Participants | Vortioxetine |
|---|---|
| Mouthfeel — Really bad | 11 |
| Mouthfeel — Bad | 17 |
| Mouthfeel — Neither good or bad | 38 |
| Mouthfeel — Good | 55 |
| Mouthfeel — Very good | 32 |
| Aftertaste — Really bad | 13 |
| Aftertaste — Bad | 26 |
| Aftertaste — Neither good or bad | 54 |
| Aftertaste — Good | 32 |
| Aftertaste — Very good | 28 |
| Smell — Really bad | 4 |
| Smell — Bad | 4 |
| Smell — Neither good or bad | 37 |
| Smell — Good | 59 |
| Smell — Very good | 49 |
| Taste — Really bad | 13 |
| Taste — Bad | 15 |
| Taste — Neither good or bad | 33 |
| Taste — Good | 60 |
| Taste — Very good | 32 |
The acceptability of vortioxetine oral drops was assessed after intake of a single dose (5 to 20 mg) corresponding to the participant's current vortioxetine dose (replacing the vortioxetine tablet on that day). The acceptability assessment was based on 3 items; acceptability of the taste, whether the drops were perceived as easy to take, willingness to take the drops every day (provided it was the only available formulation). For each item the response options were no, not sure, and yes. The oral drops were considered acceptable if \<60% of participants responded "no" to each of the 3 questions regarding acceptability.
| participants | Vortioxetine |
|---|---|
| Willingness to take the drops every day: No | 27 |
| Willingness to take the drops every day: Not sure | 17 |
| Willingness to take the drops every day: Yes | 109 |
| Easy to take medicine: No | 8 |
| Easy to take medicine: Neither easy or difficult | 10 |
| Easy to take medicine: Yes | 135 |
| Acceptability of the taste: No | 31 |
| Acceptability of the taste: Not sure | 24 |
| Acceptability of the taste: Yes | 98 |
Collected over Baseline up to Week 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine | 0/662 (0%) | 14/662 (2.1%) | 255/662 (38.5%) |
| Event | Vortioxetine |
|---|---|
| Suicidal ideationPsychiatric disorders | 4/662 |
| Suicide attemptPsychiatric disorders | 4/662 |
| Intentional overdoseInjury, poisoning and procedural complications | 3/662 |
| ArthropathyMusculoskeletal and connective tissue disorders | 1/662 |
| OsteitisMusculoskeletal and connective tissue disorders | 1/662 |
| TorticollisMusculoskeletal and connective tissue disorders | 1/662 |
| Psychomotor hyperactivityNervous system disorders | 1/662 |
| Major depressionPsychiatric disorders | 1/662 |
| ManiaPsychiatric disorders | 1/662 |
| Psychogenic seizurePsychiatric disorders | 1/662 |
| Event | Vortioxetine |
|---|---|
| NauseaGastrointestinal disorders | 138/662 |
| HeadacheNervous system disorders | 116/662 |
| VomitingGastrointestinal disorders | 69/662 |
| Abdominal painGastrointestinal disorders | 46/662 |
| NasopharyngitisInfections and infestations | 46/662 |
| DizzinessNervous system disorders | 38/662 |
All-patients-treated set (APTS) included all participants who took at least 1 dose of vortioxetine in this study 12712A.
| Age, Continuous(years) | Vortioxetine |
|---|---|
| Mean | 12.33 ± 3.07 |
| Age, Customized(Participants) | Vortioxetine |
|---|---|
| Children (7-11 years) | 300 |
| Adolescents (12-17 years) | 352 |
| Adults (18-64 years) | 10 |
| Sex: Female, Male(Participants) | Vortioxetine |
|---|---|
| Female | 361 |
| Male | 301 |
| Race/Ethnicity, Customized(Participants) | Vortioxetine |
|---|---|
| White | 447 |
| Black | 8 |
| Asian | 5 |
| Other | 188 |
| Unknown | 9 |
| Not reported | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Mar 2022, 67 months.
Results were first posted in Dec 2022, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine